StockNews.AI
FMC
StockNews.AI
202 days

FMC ALERT: Bragar Eagel & Squire, P.C. is Investigating FMC Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. FMC faces potential class action over alleged fiduciary breaches by its board. 2. Blue Orca report claims FMC concealed significant legal defeats and patent losses. 3. FMC's flagship products, which generate 40% of revenues, now face generic competition. 4. After revelations, FMC's stock fell 12.18%, losing approximately $630 million in market value. 5. Recent Q3 guidance cut indicates ongoing negative sales trends in key markets.

6m saved
Insight
Article

FAQ

Why Very Bearish?

Legal challenges and loss of patent protections severely undermine FMC's market position, echoing past incidents like Abbot Labs after similar disclosures.

How important is it?

Class actions against FMC and patent issues indicate serious implications for financial stability and investor trust.

Why Short Term?

Immediate reactions suggest rapid market adjustments, similar to prior events where stocks plummeted post-negative news.

Related Companies

NYSE:FMCNYSE:ABBVNYSE:AGRO
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FMC Corporation (NYSE: FMC) on behalf of long-term stockholders following a class action complaint that was filed against FMC on November 9, 2023 with a Class Period from February 9, 2022 to October 30, 2023. Our investigation concerns whether the board of directors of FMC have breached their fiduciary duties to the company. On September 7, 2023, Blue Orca Capital published a report, alleging that FMC and its executives had made a series of false statements about the status of patent protections for FMC’s flagship products following legal defeats in India, China and Brazil that the Company had concealed from investors. The Blue Orca Report emphasized that the products at issue, patented diamides (a class of insecticide), “account for almost 40% of FMC’s. . . revenues” in the past year and an estimated “60+% of reported EBITDA” and that FMC had “concealed from investors that it [had] suffered a recent string of stunning legal defeats around the globe that have enabled competitors to now launch competing generics at prices up to 80% below the price of FMC’s flagship insecticide product” and that “contrary to the Company’s claims, FMC’s process patents do not protect its flagship product from generic competition.” The Blue Orca Report included an analysis of legal proceedings and market conditions in India, China, and Brazil. In addition to identifying a range of market headwinds affecting FMC’s prospects in such markets, the Blue Orca Report concluded that FMC and its executives repeatedly made false claims that legal victories had ensured Diamide patent protection for years to come, when, in fact, FMC’s legal losses had resulted in a loss of patent protection for its flagship products and cleared the way for generic competition. In short, Defendants repeatedly falsely reassured investors that FMC had not gone over the patent cliff while, in truth, the Company was already in free fall. Immediately following these revelations on September 7, 2023, the Company’s share price dropped more than 7.4%, to close at $76.10 per share, representing approximately $630 million in investor losses, on high trading volume. Finally, On October 23, 2023, FMC announced that it was again cutting its Q3 2023 outlook and guidance for revenues for Q4 and FY 2024, projecting earnings well below the expectations of analysts, citing substantially lower sales volumes in Latin America, particularly Brazil. On this news, FMC’s stock price fell $8.83 per share, or 12.18%, to close at $58.12 per share on October 23, 2023. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, it is alleged that Defendants failed to disclose to investors that: (1) the diminishment of patent protection for FMC’s flagship products following legal defeats in key markets including India, China, and Brazil had opened the door to increased competition from generics; (2) the Company repeatedly mislead investors about the status of such proceedings and falsely claimed that it did not and would not face generic competition in key markets until 2026 at the earliest; and (3) because of these issues Defendant’s positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you are a long-term stockholder of FMC, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News